Skip to content

What Innovative Pharmaceutical Research is Protected under the SPC-Regime? A Discussion of the ECJ's Decision in the Abraxis Case

Otto Swens, Carly van der Beek

DOI https://doi.org/10.21552/eplr/2019/2/8



Otto Swens and Carly van der Beek work as attorneys at Vondst Advocaten, Amsterdam. For correspondence: <mailto:otto.swens@vondst.com> <mailto:carly.vanderbeek@vondst.com>.

Share


Lx-Number Search

A
|
(e.g. A | 000123 | 01)

Export Citation